SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 7, 2004
Progenics Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
----------------------------------- -------------- ------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
------------------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
--------------
--------------------------------------------------------------
(Former name or former address, if changed since last report.)
Section 8 - Other Events
Item 8.01 Other Events
On October 7, 2004, Progenics Pharmaceuticals, Inc. issued a press release
announcing that the target enrollment been reached in the Phase 2 study of its
investigational drug, Methylnaltrexone for the treatment of post operative ileus
(POI). A copy of the press release is attached as Exhibit 99.1 and the
information contained therein is incorporated by reference into this Item 8.01
of this Current Report on Form 8-K.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statement and Exhibits
(c) the following exhibits are filed with this report
Exhibit Number Description
-------------- -----------
99.1 Press release dated October 7, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ ROBERT A. MCKINNEY
---------------------------------------------
Robert A. McKinney
Vice President, Finance & Operations
Date: October 7, 2004